SERNYSEPharmaceutical PreparationsFiscal year ends December 31
Serina Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.65−0.07 (-4.07%)
Close on Oct 19, 2026
- Market cap
- $27.04M
- P/E (TTM)
- –
- Dividend yield
- –
Serina Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Serina Therapeutics | Industry median |
|---|---|---|
| Market Cap | $41.91M | $166.30M |
| Enterprise Value | $18.89M | $88.19M |
Income (trailing twelve months)
| Measure | Serina Therapeutics | Industry median |
|---|---|---|
| Net Income | -$21.18M | -$22.46M |
| EPS (Diluted) | -$1.90 | -$0.83 |
Returns
| Measure | Serina Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -1175.1% | -53.2% |
| Return on Assets (ROA) | -121.9% | -40.9% |
Growth
| Measure | Serina Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | 56.4% | 2.25% |
| Revenue Growth (5Y CAGR) | -18.5% | 6.48% |
Balance sheet
| Measure | Serina Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $23.02M | $61.43M |
| Net Cash (Debt) | $23.02M | $15.35M |
| Net Cash Per Share | $0.91 | $0.66 |
| Working Capital | $21.27M | $76.81M |
Financial position
| Measure | Serina Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 6.65 | 3.34 |
| Quick Ratio | 6.12 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Serina Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$21.14M | -$12.35M |
| Capital Expenditures | -$66.00K | -$1.08M |
| Free Cash Flow | -$21.20M | -$20.22M |
| FCF Per Share | -$0.83 | -$0.42 |
Efficiency
| Measure | Serina Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.32M | -$703.34K |
| Employee Count | 16 | 74 |
Dividends and yields
| Measure | Serina Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -50.5% | -23.3% |
| FCF Yield | -50.6% | -8.72% |
Shares
| Measure | Serina Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 25,400,500 | 58,127,000 |
| Shares Change (YoY) | 24.8% | 10.9% |
| Shares Change (QoQ) | 70.5% | 0.54% |
| Float | 12,775,700 | 49,136,700 |
| Shares Held by Insiders | 49.7% | 11.6% |
| Shares Held by Institutions | 5.54% | 59.4% |
Scores
| Measure | Serina Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 0.38 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Serina Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.